Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (Nasdaq: PDSB) is a late-stage immunotherapy company developing investigational cancer therapies based on its Versamune® platform and IL-12 immunocytokine technology. News about PDS Biotech centers on the clinical and regulatory progress of its lead HPV16-targeted immunotherapy PDS0101 and its tumor-targeting IL-12 fused antibody drug conjugate PDS01ADC.
On this page, readers can follow company announcements on pivotal and mid-stage trials, including the VERSATILE-002 Phase 2 study and the VERSATILE-003 Phase 3 trial in HPV16-positive recurrent and/or metastatic head and neck squamous cell cancers. Updates often cover final survival and progression-free survival data, sub-analyses in specific patient subgroups such as low PD-L1 (CPS 1–19) cohorts, and efforts to align with the U.S. Food and Drug Administration on potential accelerated approval pathways.
PDS Biotech news also highlights translational research presented at scientific meetings like the Society for Immunotherapy of Cancer, where investigators have reported immune biomarker signatures, natural killer cell reprogramming, and expansion of stem-like memory T cells associated with PDS0101 and PDS01ADC. Additional coverage includes National Cancer Institute-led Phase 2 trials in metastatic colorectal and other advanced solid tumors, intellectual property developments such as new composition of matter patents for PDS0101, and capital markets events including registered direct offerings disclosed in Form 8-K filings.
Investors and observers who want to track PDSB can use this news feed to monitor clinical milestones, regulatory interactions, scientific data presentations, and financing activities that may influence the company’s development programs and overall outlook.
PDS Biotechnology Corporation (Nasdaq: PDSB) has appointed Dr. Olivera Finn and Dr. Mark Frohlich to its Scientific Advisory Board, enhancing its leadership in cancer immunotherapy. Dr. Finn, a distinguished immunologist, brings over 30 years of experience, notably in T-cell research. Dr. Frohlich, a medical oncologist, has over 20 years in developing immunotherapies and contributed to the FDA approval of Provenge®. These appointments are poised to accelerate the development of PDSB's clinical programs, particularly PDS0101 for HPV-associated cancers and PDS0102 for prostate cancer.
PDS Biotechnology Corporation (Nasdaq: PDSB) has received $4.5 million from the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program. This funding will support the advancement of its immuno-oncology pipeline, including the lead candidate PDS0101, which is in Phase 2 clinical studies for HPV-associated cancers. The NOL program allows qualifying New Jersey-based biotechnology firms to convert tax losses into cash to enhance growth. PDS Biotech is among 49 companies benefiting from approximately $54.5 million approved for the 2020 period.
PDS Biotechnology Corporation (PDSB) reported a $3.0 million net loss for Q1 2021, down from $4.0 million in Q1 2020. R&D expenses decreased 28% to $1.4 million, and G&A expenses fell 21% to $1.6 million. Total operating expenses were 24% lower at $3.0 million. The company's cash balance stood at $25.0 million as of March 31, 2021. PDSB will present interim data of its PDS0101 Phase 2 clinical trial at the ASCO 2021 Annual Meeting on June 7.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in Noble Capital Markets' C-Suite Interview Series, where leadership discussed the company's pipeline and proprietary Versamune® technology. Key topics included the ongoing phase 2 trials of PDS0101 and the anticipated interim data readout from a National Cancer Institute-led trial at ASCO in June. The interview is available on Channelchek and PDS Biotech's website. PDS0101 is being evaluated in partnership with Merck for HPV-associated cancers.
PDS Biotechnology Corporation (PDSB) announced that efficacy and safety data from the NCI's Phase 2 study of PDS0101 for advanced HPV-associated cancers has been accepted for oral presentation at the ASCO 2021 Annual Meeting, scheduled for June 4-8. The trial demonstrated preliminary efficacy with a response from 3 of the first 8 patients, leading to expanded enrollment. The study focuses on a combination of PDS0101, M9241, and bintrafusp alfa. Dr. Lauren V. Wood expressed optimism regarding the study's potential in immunotherapy.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the release of its financial results for Q1 2021 on May 13, 2021, prior to market open. Following this release, management will conduct a conference call at 8:00 am ET to discuss the results and provide a business update. The call will also be available as a live webcast, and an archived version will be accessible on the company’s website for six months. PDS Biotech focuses on developing cancer therapies and vaccines using its proprietary Versamune® T-cell activating technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) will participate in Noble Capital Markets’ Virtual Road Show on April 21, 2021, at 1 PM EDT. The event includes a corporate presentation by CEO Dr. Frank Bedu-Addo, CMO Dr. Lauren Wood, and CFO Seth Van Voorhees, followed by a Q&A session. Registration is free for all investors. PDS Biotech focuses on developing cancer therapies and infectious disease vaccines using its proprietary Versamune® technology, which activates T-cells and enhances immune responses. For more information, visit their website.
PDS Biotechnology Corporation (Nasdaq: PDSB) reported its financial results for the year ending December 31, 2020, revealing a net loss of $14.8 million ($0.89 per share), a rise from a $7.0 million loss in 2019. R&D expenses increased to $7.9 million, while G&A expenses decreased to $7.0 million. Key developments include the initiation of Phase 2 trials for PDS0101 in combination with KEYTRUDA® and chemoradiotherapy. Additionally, PDSB received a $60 million commitment from Brazil’s Ministry of Science, Technology and Innovation for the development of its COVID-19 vaccine PDS0203.
PDS Biotech, along with Farmacore Biotechnology and Blanver Farmoquímica, announced a commitment of approximately US$60 million from Brazil's MCTI for the development of a second-generation COVID-19 vaccine utilizing the Versamune® technology. The funding will support a combined Phase 1/2 clinical trial expected to begin in Q2/3 2021, pending approval by Anvisa. The trial aims to enroll around 360 patients, focusing on the vaccine's safety and efficacy. The consortium plans to scale up manufacturing in anticipation of positive trial results.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy firm, will announce its financial results for the year ended December 31, 2020, on March 18, 2021, before market opening. The announcement will be followed by a conference call at 8:00 am ET to discuss the results and provide a business update. PDS Biotech focuses on innovative cancer therapies and vaccines using its proprietary Versamune® technology, designed to activate immune responses effectively.
FAQ
What is the current stock price of Pds Biotechnology Corporation (PDSB)?
What is the market cap of Pds Biotechnology Corporation (PDSB)?
